RARITAN, N.J., June 19, 2013 /PRNewswire/ — Janssen Research & Development, LLC (Janssen) today announced that a study published online in The New England Journal of Medicine (NEJM) demonstrates treatment with ibrutinib, an investigational oral Bruton’s tyrosine kinase (BTK)…

Load More Related Articles
Load More In Entertainment